These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35000613)

  • 1. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
    Möhn N; Bonda V; Grote-Levi L; Panagiota V; Fröhlich T; Schultze-Florey C; Wattjes MP; Beutel G; Eder M; David S; Körner S; Höglinger G; Stangel M; Ganser A; Koenecke C; Skripuletz T
    Neurol Res Pract; 2022 Jan; 4(1):1. PubMed ID: 35000613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
    Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Early Neurological Indicator of Immune Effector Cell-Associated Neurotoxicity Syndrome.
    Yorichika Y; Neshige S; Edahiro T; Aoki S; Maruyama H
    Cureus; 2024 Mar; 16(3):e57298. PubMed ID: 38690494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy.
    Larue M; Bouvier A; Maillard A; Cuffel A; Allain V; Ursu R; Carpentier AF; Azoulay E; Thieblemont C; Di Blasi R; Caillat-Zucman S
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39317455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
    Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
    Pennisi M; Sanchez-Escamilla M; Flynn JR; Shouval R; Alarcon Tomas A; Silverberg ML; Batlevi C; Brentjens RJ; Dahi PB; Devlin SM; Diamonte C; Giralt S; Halton EF; Jain T; Maloy M; Mead E; Palomba ML; Ruiz J; Santomasso B; Sauter CS; Scordo M; Shah GL; Park JH; Yanez San Segundo L; Perales MA
    Blood Adv; 2021 Sep; 5(17):3397-3406. PubMed ID: 34432870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EASIX and m-EASIX Predict CRS and ICANS in Pediatric and AYA Patients post CD19-CAR T cell Therapy.
    Zandaki D; Selukar S; Bi Y; Li Y; Zinsky M; Bonifant CL; Epperly R; Keerthi D; Triplett BM; Gottschalk S; Naik S; Talleur AC
    Blood Adv; 2024 Sep; ():. PubMed ID: 39325974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma.
    Morbelli S; Gambella M; Raiola AM; Ghiggi C; Bauckneht M; Raimondo TD; Lapucci C; Sambuceti G; Inglese M; Angelucci E
    J Neuroimaging; 2023; 33(5):825-836. PubMed ID: 37291470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
    Sales C; Anderson MA; Kuznetsova V; Rosenfeld H; Malpas CB; Roos I; Dickinson M; Harrison S; Kalincik T
    Eur J Neurol; 2024 Mar; 31(3):e16174. PubMed ID: 38085272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
    Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.
    Pensato U; Amore G; Muccioli L; Sammali S; Rondelli F; Rinaldi R; D'Angelo R; Nicodemo M; Mondini S; Sambati L; Asioli GM; Rossi S; Santoro R; Cretella L; Ferrari S; Spinardi L; Faccioli L; Fanti S; Paccagnella A; Pierucci E; Casadei B; Pellegrini C; Zinzani PL; Bonafè M; Cortelli P; Bonifazi F; Guarino M
    J Neurol; 2023 May; 270(5):2659-2673. PubMed ID: 36869888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Kinetics of Inflammation-Related Proteins and Cytokines in Children Undergoing CAR-T Cell Therapy-Are They Biomarkers of Therapy-Related Toxicities?
    Marschollek P; Liszka K; Mielcarek-Siedziuk M; Dachowska-Kałwak I; Haze N; Panasiuk A; Olejnik I; Jarmoliński T; Frączkiewicz J; Gamrot Z; Radajewska A; Bil-Lula I; Kałwak K
    Biomedicines; 2024 Jul; 12(7):. PubMed ID: 39062195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
    Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
    Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome.
    Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C
    Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
    Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
    J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL.
    Sheth VS; Gauthier J
    Bone Marrow Transplant; 2021 Mar; 56(3):552-566. PubMed ID: 33230186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.